even after adjusting for major risk factors, the reduction in the risk of cardiovascular events (hr, 0.47; 95% ci, 0.24-0.90; p =.02) and hypertension (hr, 0.62; 95% ci, 0.45-0.86; p =.004) associated with acarbose treatment was still statistically significant.